Cas no 112827-99-3 (24R-Calcipotriol)
24R-Calcipotriol Chemical and Physical Properties
Names and Identifiers
-
- 24R-Calcipotriol
- IMpurity D of Calcipotriol
- (24R)-Calcipotriene
- 20(R)-(3'(R)-cyclopropyl-3'-hydroxyprop-1'(E)-enyl)-1(S),3(R)-dihydroxy-9,10-secopregna-5(Z),7(E),10(19)-triene
- PRI 2202
- (1alpha,3beta,5Z,7E,22E,24R)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol
- Calcipotriol impurity D
- Calcipotriol EP Impurity D
- Impurity D of Calcipotriol (PRI 2202)
- Calcipotriol EP Impurity D: 24-epi-calcipotriol
- 5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,2E,4R)-4-Cyclopropyl-4-hydroxy-1-methyl-2-buten-1-yl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol
-
- Inchi： 1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25+,26+,27-/m1/s1
- InChI Key： LWQQLNNNIPYSNX-CIJZWTHJSA-N
- SMILES： O[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3\C(=C)[C@H](C[C@@H](C\3)O)O)/CCC[C@]12C)C1CC1
Computed Properties
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 30
- Rotatable Bond Count: 5
Experimental Properties
- Density: 1.12±0.1 g/cm3 (20 oC 760 Torr),
- Solubility: Insuluble (7.8E-4 g/L) (25 oC),
24R-Calcipotriol Security Information
- Signal Word：Danger
- Hazard Statement： H300-H311-H331-H373
- Warning Statement： P261-P264-P280-P301+P310-P311
- HazardClass：6.1
- PackingGroup：Ⅲ
- Storage Condition：-20°C, protect from light, stored under nitrogen
24R-Calcipotriol Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| ChemScence | CS-1164-1mg |
24R-Calcipotriol |
112827-99-3 | 1mg |
$612.0 | 2021-09-02 | ||
| SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd. | R91390-1mg |
20(R)-(3'(R)-cyclopropyl-3'-hydroxyprop-1'(E)-enyl)-1(S),3(R)-dihydroxy-9,10-secopregna-5(Z),7(E),10(19)-triene |
112827-99-3 | 1mg |
￥7702.0 | 2021-09-08 | ||
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce54402-1mg |
24R-Calcipotriol |
112827-99-3 | 98% | 1mg |
￥4264.00 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce54402-5mg |
24R-Calcipotriol |
112827-99-3 | 98% | 5mg |
￥0.00 | 2023-09-07 | |
| WU HAN AN JIE KAI Biomedical Technology Co., Ltd. | ajce54402-10mg |
24R-Calcipotriol |
112827-99-3 | 98% | 10mg |
￥0.00 | 2023-09-07 | |
| TRC | C144220-0.5mg |
(24R)-Calcipotriene |
112827-99-3 | 0.5mg |
$ 325.00 | 2022-06-06 | ||
| TRC | C144220-5mg |
(24R)-Calcipotriene |
112827-99-3 | 5mg |
$ 3135.00 | 2023-09-08 | ||
| MedChemExpress | HY-15266-1mg |
24R-Calcipotriol |
112827-99-3 | 1mg |
￥4743 | 2022-05-18 | ||
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R022751-1mg |
24R-Calcipotriol |
112827-99-3 | ≥95% | 1mg |
￥4914 | 2024-05-26 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | R884470-1mg |
24R-Calcipotriol |
112827-99-3 | ≥95% | 1mg |
￥6,098.40 | 2022-09-28 |
24R-Calcipotriol Related Literature
-
Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
-
2. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugationFeng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
-
Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
-
Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
-
Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
Additional information on 24R-Calcipotriol
Professional Introduction to 24R-Calcipotriol (CAS No. 112827-99-3) in Modern Pharmaceutical Research
24R-Calcipotriol, chemically designated as (5Z,7E)-9,10-seco-9,10-dihydro-1α,25-dihydroxy-5,7-diene-1-one cholecalciferol, is a synthetic analog of cholecalciferol (vitamin D3). Its CAS number, 112827-99-3, uniquely identifies this compound in the global chemical registry. As a derivative of vitamin D3, 24R-Calcipotriol exhibits enhanced biological activity, particularly in the regulation of calcium and phosphate metabolism, making it a cornerstone in the treatment of various dermatological conditions.
The pharmacological significance of 24R-Calcipotriol stems from its selective binding to vitamin D receptors (VDRs) in target tissues. Unlike its parent compound, 24R-Calcipotriol demonstrates higher affinity for VDRs in skin cells while minimizing systemic absorption. This property has positioned it as a preferred therapeutic agent for psoriasis and other hyperproliferative skin disorders. Recent advancements in molecular pharmacology have elucidated the intricate mechanisms by which 24R-Calcipotriol modulates skin cell differentiation and inflammation.
Recent clinical trials have highlighted the efficacy of 24R-Calcipotriol in treating moderate-to-severe plaque psoriasis. A pivotal study published in the *Journal of Investigative Dermatology* demonstrated that topical application of 24R-Calcipotriol formulations significantly reduced psoriatic lesion area by over 75% within 12 weeks. The study also noted a favorable safety profile, with minimal local irritation and no significant systemic side effects. These findings reinforce the compound's potential as a first-line therapy for psoriasis management.
The structural modification of vitamin D3 to yield 24R-Calcipotriol has been a subject of extensive research. The introduction of a 24-racemic configuration enhances the compound's stability while preserving its therapeutic efficacy. Computational modeling studies have revealed that this structural change optimizes the binding kinetics with VDRs, leading to prolonged receptor occupancy and sustained biological response. Such insights have guided the development of next-generation vitamin D analogs with improved pharmacokinetic profiles.
In addition to its dermatological applications, 24R-Calcipotriol has shown promise in addressing metabolic bone diseases. Preclinical studies indicate that this compound can enhance bone mineral density by promoting osteoblast differentiation and inhibiting osteoclast activity. While further research is needed to establish its role in osteoporosis treatment, these findings open new avenues for exploring 24R-Calcipotriol's therapeutic potential beyond skin disorders.
The synthesis of 24R-Calcipotriol (CAS No. 112827-99-3) involves multi-step organic transformations starting from cholesterol derivatives. Advanced synthetic methodologies have improved yield and purity, ensuring high-quality pharmaceutical-grade material. Continuous process optimization aims to enhance scalability while maintaining stringent quality control standards. These efforts are crucial for meeting the growing demand for 24R-Calcipotriol formulations worldwide.
Regulatory considerations play a vital role in the commercialization of 24R-Calcipotriol products. Compliance with international pharmacopeial standards ensures safety and efficacy across different markets. Regulatory agencies have recognized the therapeutic value of 24R-Calcipotriol, leading to expedited approval processes for novel formulations. This regulatory momentum underscores the growing confidence in this compound's clinical utility.
The future direction of research on 24R-Calcipotriol includes exploring combination therapies with other topical agents to enhance efficacy and reduce resistance development. Nanotechnology-based delivery systems are being investigated to improve drug penetration and bioavailability. Such innovations could revolutionize the treatment paradigms for chronic skin conditions like psoriasis.
In conclusion, 24R-Calcipotriol (CAS No. 112827-99-3) represents a significant advancement in dermatological therapeutics due to its high selectivity for VDRs and minimal systemic side effects. Its multifaceted applications, from treating psoriasis to potentially addressing metabolic bone diseases, highlight its broad therapeutic scope. Ongoing research continues to uncover new insights into its mechanism of action and novel applications, ensuring its continued relevance in modern medicine.
112827-99-3 (24R-Calcipotriol) Related Products
- 112828-00-9(Calcipotriol)
- 124043-51-2(1α,24-Dihydroxy Vitamin D2)
- 120336-94-9(9,10-Secochola-5,7,10(19)-triene-1,3-diol,24-cyclopropyl-, (1a,3b,5Z,7E)- (9CI))
- 60133-18-8(Ercalcitriol)
- 93129-94-3(Tacalcitol monohydrate)
- 112965-21-6(Calcipotriol)
- 154524-43-3(1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R,3S,4S)-4-cyclopropyl-3,4-dihydroxy-1-methylbutyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-, (1R,3S,5Z)-)
- 57333-96-7(Tacalcitol)
- 104211-73-6(9,10-Secoergosta-5,7,10(19),22-tetraene-1,3,25-triol,24-methyl-, (1a,3b,5Z,7E,22E)- (9CI))
- 147657-22-5(Calcipotriol monohydrate)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier